Clarity on When to Start ART in Active TB
For HIV/TB-coinfected patients with advanced immunosuppression, the survival benefit of starting ART within the first 2 weeks after initiation of TB therapy outweighs the risks for IRIS and other adverse events.
Welcome to Journal Watch. The content you requested requires sign in with a username and password.
Sign In
Sign Up
Print subscribers
Activate your free online account for full access to all site content and features.
Other visitors
Subscribe for full access to all site content and features. ($99/year)
Purchase a site pass for full access to all articles. ($19/7 days)
Or, simply register for free access to email alerts, site features, and article archives. (FREE)
